Overview of the 2022 WHO classification of neuroendocrine neoplasms
In this review, we detail the changes and the relevant features that are applied to
neuroendocrine neoplasms (NENs) in the 2022 WHO Classification of Endocrine and …
neuroendocrine neoplasms (NENs) in the 2022 WHO Classification of Endocrine and …
Thyroid cancer
The past 5–10 years have brought in a new era in the care of patients with thyroid cancer,
with the introduction of transformative diagnostic and management options. Several …
with the introduction of transformative diagnostic and management options. Several …
[HTML][HTML] First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …
[HTML][HTML] Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
J Hadoux, R Elisei, MS Brose, AO Hoff… - … England Journal of …, 2023 - Mass Medical Soc
Background Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …
Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology
Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of
choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation …
choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation …
2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer: American thyroid association anaplastic thyroid cancer …
KC Bible, E Kebebew, J Brierley, JP Brito… - Thyroid, 2021 - liebertpub.com
Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid
cancer. Since the guidelines for the management of ATC by the American Thyroid …
cancer. Since the guidelines for the management of ATC by the American Thyroid …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2 …
Background Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS
activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions …
activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions …
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
L Huang, S Jiang, Y Shi - Journal of hematology & oncology, 2020 - Springer
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
V Subbiah, MI Hu, LJ Wirth, M Schuler… - The lancet Diabetes & …, 2021 - thelancet.com
Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …